Skip to main content
Skip to content

Duplicate Document

This document appears to be a copy. The original version is:

Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017)
Case File
kaggle-ho-024690House Oversight

Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017)

Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017) The passage is a routine industry summary of approved cannabinoid drugs and their regulatory status. It contains no specific allegations, names of officials, financial transactions, or controversial actions that would merit investigative follow‑up. Consequently it offers negligible investigative value. Key insights: Lists FDA‑approved cannabinoid medicines: Marinol, Syndros, Cesamet, Sativex.; Notes schedule classifications under the U.S. Controlled Substances Act.; Mentions GW Pharmaceuticals as manufacturer of Sativex.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024690
Pages
1
Persons
1
Integrity
No Hash Available

Summary

Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017) The passage is a routine industry summary of approved cannabinoid drugs and their regulatory status. It contains no specific allegations, names of officials, financial transactions, or controversial actions that would merit investigative follow‑up. Consequently it offers negligible investigative value. Key insights: Lists FDA‑approved cannabinoid medicines: Marinol, Syndros, Cesamet, Sativex.; Notes schedule classifications under the U.S. Controlled Substances Act.; Mentions GW Pharmaceuticals as manufacturer of Sativex.

Tags

kagglehouse-oversightcannabispharmaceuticalsfdacontrolled-substancesdrug-approval

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
KR L PI L AC EL CA TA Cannabis Investment Report | December 2017 Pharmaceuticals Cannabinoid-based pharmaceuticals are drugs containing cannabinoids or cannabinoid-like com- pounds that are either derived from natural cannabis or chemically synthesized. A handful of such drugs have been approved for use to treat certain medical conditions both in the United States and elsewhere. Examples of cannabinoid-based pharmaceuticals that have been approved for use in various countries include Marinol, Syndros, Cesamet and Sativex. Another cannabinoid-based pharmaceuti- cal, Epidiolex, has not yet been approved but could become the first medicine derived from the canna- bis plant to be approved by the U.S. Food and Drug Administration (FDA). The drug Marinol is comprised of dronabinol (a synthetic THC) encapsulated with sesame oil in a soft gelatin capsule. Marinol has been approved by the FDA for use in treating (i) anorexia associated with weight loss in patients with AIDS and (ii) nausea and vomiting associated with cancer chemo- therapy. Marinol is a Schedule HI controlled substance under the U.S. Controlled Substances Act (CSA). Syndros is a drug that contains dronabinol in a liquid solution; it has been approved by the FDA for use by adults in treating the same symptoms for which Marinol has been approved. Syndros is a Schedule II controlled substance under the CSA. Forms of dronabinol have been approved for use in jurisdictions outside the United States, including Canada and Denmark. Cesamet is a drug made up of encapsulated nabilone, a synthetic cannabinoid similar to THC. Cesamet has been approved by the FDA for use in treating nausea and vomiting associated with cancer chemotherapy. Cesamet is a Schedule II controlled substance under the CSA. Forms of nabilone have been approved for use in jurisdictions outside the United States, including Australia, Canada, Mexico and the United Kingdom. Sativex is a mouth spray used for treatment of spasticity caused by multiple sclerosis; it includes THC and CBD derived from cannabis. Sativex was first approved for use in the United Kingdom in 2010, and has been approved for use in at least 30 countries (but not in the United States). Sativex is manufactured by U.K.-based GW Pharmaceuticals and is generally recognized as the first prescription drug in the world to include plant-based cannabinoids. The cannabis extract used in Sativex is a Sched- ule I controlled substance under the CSA. SS ative X 2zmgiasma Solucién para pulverizacion bucal ® pelta-9-tetrahidrocannabinol - - Cannabidiol : , mh 3 envases pulverizadores de 13h | R =) riled ¥ er] Via bucal | b GAlmirall Pharmaceuticals 54 © 2017 Ackrell Capital, LLC | Member FINRA/SIPC

Related Documents (6)

House OversightUnknown

Alleged British Intelligence (Tavistock) and LaRouche Network Ties to 1950s Pornography and 1970s Anti‑Nuclear Protest Briefings

Alleged British Intelligence (Tavistock) and LaRouche Network Ties to 1950s Pornography and 1970s Anti‑Nuclear Protest Briefings The passage links a historic British intelligence institute (Tavistock) to U.S. political activist Lyndon LaRouche’s private intelligence network and claims they briefed state police on a 1970s anti‑nuclear protest. It provides specific names and a concrete event, offering a potential investigative angle (e.g., archival search for Tavistock‑related projects, LaRouche intelligence files, police briefing records). However, the claims are vague, lack dates, documents, or transaction details, and the Tavistock‑pornography connection is a long‑standing conspiracy trope, reducing novelty and verifiability. Key insights: Paul Krassner allegedly recruited by the Tavistock Institute in the early 1950s for pornographic satire.; Lyndon LaRouche’s private intelligence network reportedly briefed a state police lieutenant before a 1970s Seabrook nuclear plant protest.; The U.S. Labor Party’s newsletter was allegedly subscribed to by police departments nationwide.

1p
House OversightUnknown

Synthetic Cannabis Overview Lacks Investigative Leads

Synthetic Cannabis Overview Lacks Investigative Leads The document is a generic informational summary about cannabinoids with no mention of individuals, transactions, or wrongdoing. It provides no actionable leads, novel allegations, or connections to powerful actors. Key insights: Describes types of cannabinoids and FDA approvals.; Lists potential therapeutic uses of various phytocannabinoids.; Cites Cowen and Company as source.

1p
House OversightUnknown

Florida Aquifer Water Plant Option – Minimal Oversight Detail

Florida Aquifer Water Plant Option – Minimal Oversight Detail The passage contains only generic references to a water plant option and associated costs for the Town of Palm Beach, with no mention of influential actors, financial flows, or misconduct. It offers no actionable leads for investigation. Key insights: Mentions a proposed water plant for the Floridan aquifer.; Notes additional capital and operational costs for Palm Beach.; Uses generic descriptors: secure, reliable, sustainable.

1p
House OversightOtherNov 11, 2025

Alleged British Intelligence (Tavistock) and LaRouche Network Ties to 1950s Pornography and 1970s Anti‑Nuclear Protest Briefings

The passage links a historic British intelligence institute (Tavistock) to U.S. political activist Lyndon LaRouche’s private intelligence network and claims they briefed state police on a 1970s anti‑n Paul Krassner allegedly recruited by the Tavistock Institute in the early 1950s for pornographic sat Lyndon LaRouche’s private intelligence network reportedly briefed a state police lieutenant before

1p
House OversightOtherNov 11, 2025

Scientific overview of CBD pharmacology and clinical trials

The passage provides general medical information about CBD and mentions pharmaceutical companies, but contains no specific allegations, financial flows, or connections to powerful officials. It offers Describes the endocannabinoid system and CBD's mechanism of action. Lists FDA‑approved CBD drug (Epidiolex) and companies conducting trials. Notes safety profile and potential drug‑interaction risks

1p
House OversightUnknown

Erdogan frames Syria as Turkey's domestic issue amid 2011 unrest

Erdogan frames Syria as Turkey's domestic issue amid 2011 unrest The passage is a newspaper commentary offering general political analysis without specific names, dates, transactions, or actionable leads. It repeats known public statements by Erdogan and provides no novel evidence of misconduct or financial flows. Key insights: Erdogan compared Libya and Syria, calling Syria a domestic issue for Turkey.; The AKP government waived visa requirements with Syria, citing a vision of a Middle Eastern union.; The article mentions 250 Syrian refugees entering Turkey.

1p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.